Punicalagin treats postmenopausal osteoporosis by promoting osteogenesis

doi:10.12307/2024.438

Abstract

Abstract: BACKGROUND: Punicalagin has a wide range of effects and high safety, but its effect on osteoblasts and postmenopausal osteoporosis is unknown.
OBJECTIVE: To investigate the effect of punicalagin on osteoblasts and postmenopausal osteoporosis.
METHODS: The effect of punicalagin on the proliferation of MC3T3-E1 cells was detected. Punicalagin was added to the osteogenic induction medium to detect its effect on osteogenic differentiation. Punicalagin was used to treat ovariectomized rats and Micro CT scan and serum procollagen type 1 N-terminal propeptide test were performed after 3 months to detect the therapeutic effect.
RESULTS AND CONCLUSION: Cell counting kit-8 assay showed that punicalagin could promote the proliferation of osteoblasts (P < 0.05). The results of qRT-PCR and western blot showed that punicalagin could promote the mRNA and protein expressions of alkaline phosphatase and Runx2 in osteoblasts (P < 0.05). The results of Micro CT scan and serological test showed that punicalagin could improve bone mineral density, bone volume fraction, trabecular thickness, trabecular number and procollagen type 1 N-terminal propeptide level of ovariectomized rats. To conclude, punicalagin can promote osteoblast proliferation and differentiation, and have therapeutic effects in postmenopausal osteoporosis rats.

Key words: punicalagin, postmenopausal osteoporosis, ovariectomy, osteoblast, procollagen type 1 N-terminal propeptide

CLC Number:

Zhang Shudong, Huang Yilin, Yao Qi. Punicalagin treats postmenopausal osteoporosis by promoting osteogenesis[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(26): 4101-4105.

Figures/Tables 3

References

[1] LEBOFF MS, GREENSPAN SL, INSOGNA KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-2102.
[2] MA ML, MA ZJ, HE YL, et al. Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2022;10:979649.
[3] XU H, LIU T, HU L, et al. Effect of caffeine on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 2019;112:108650.
[4] WANG H, YANG L, CHAO J. Antiosteoporosis and bone protective effect of dieckol against glucocorticoid-induced osteoporosis in rats. Front Endocrinol. 2022;13:932488.
[5] WU D, CLINE-SMITH A, SHASHKOVA E, et al. T-Cell Mediated Inflammation in Postmenopausal Osteoporosis. Front Immunol. 2021; 12:687551.
[6] YANG K, QIU X, CAO L, et al. The role of melatonin in the development of postmenopausal osteoporosis. Front Pharmacol. 2022;13:975181.
[7] WANG X, ZHANG X, HAN Y, et al. Role of the major histocompatibility complex class II protein presentation pathway in bone immunity imbalance in postmenopausal osteoporosis. Front Endocrinol. 2022; 13:876067.
[8] LIM SY. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk. Womens Health. 2022;18:17455057221125577.
[9] ROZENBERG S, AL-DAGHRI N, AUBERTIN-LEHEUDRE M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. Osteoporos Int. 2020;31(12):2271-2286.
[10] FISCHER V, HAFFNER-LUNTZER M. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis. Semin Cell Dev Biol. 2022;123:14-21.
[11] 麦合木提江•穆海麦提,买买提沙吾提阿吉•买买提,唐军伟,等.has-miR-100-5p靶向含7A的锌指和BTB结构域是绝经后骨质疏松的潜在靶标[J].中国组织工程研究,2023,27(32):5168-5172.
[12] YUAN F, PENG W, YANG C, et al. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg. 2019;66:1-11.
[13] AIBAR-ALMAZÁN A, VOLTES-MARTÍNEZ A, CASTELLOTE-CABALLERO Y, et al. Current Status of the Diagnosis and Management of Osteoporosis. Int J Mol Sci. 2022;23(16):9465.
[14] SILVA BC, MADEIRA M, D’ALVA CB, et al. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO). Arch Endocrinol Metab. 2022;66(5):591-603.
[15] 许萍,杨成武,黄淑芸,等.安石榴苷基于调整肠道菌群改善APP/PS1阿尔兹海默病小鼠认知功能的实验研究[J].中国临床药理学杂志,2022,38(18):2181-2186.
[16] BERDOWSKA I, MATUSIEWICZ M, FECKA I. Punicalagin in Cancer Prevention-Via Signaling Pathways Targeting. Nutrients. 2021;13(8): 2733.
[17] ALALAWI S, ALBALAWI F, RAMJI DP. The Role of Punicalagin and Its Metabolites in Atherosclerosis and Risk Factors Associated with the Disease. Int J Mol Sci. 2023;24(10):8476.
[18] BHATNAGAR A, KEKATPURE AL. Postmenopausal Osteoporosis: A Literature Review. Cureus. 2022;14(9):e29367.
[19] SUN D, PENG Y, GE S, et al. USP1 Inhibits NF-κB/NLRP3 Induced Pyroptosis through TRAF6 in Osteoblastic MC3T3-E1 Cells. J Musculoskelet Neuronal Interact. 2022;22(4):536-545.
[20] ALI D, TENCEROVA M, FIGEAC F, et al. The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of increased bone marrow adiposity. Front Endocrinol. 2022;13:981487.
[21] YANG X, CHANG T, YUAN Q, et al. Changes in the composition of gut and vaginal microbiota in patients with postmenopausal osteoporosis. Front Immunol. 2022;13:930244.
[22] ZHENG L, ZHUANG Z, LI Y, et al. Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis. Bioact Mater. 2021;14:250-261.
[23] JEONG HG, KIM MK, LIM HJ, et al. Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal Women. J Menopausal Med. 2022;28(3):85-91.
[24] XU J, CAO K, LIU X, et al. Punicalagin Regulates Signaling Pathways in Inflammation-Associated Chronic Diseases. Antioxidants. 2021; 11(1):29.
[25] LO J, LIU CC, LI YS, et al. Punicalagin Attenuates LPS-Induced Inflammation and ROS Production in Microglia by Inhibiting the MAPK/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. J Inflamm Res. 2022;15:5347-5359.
[26] AL-KHAWALDE AAA, ABUKHALIL MH, JGHEF MM, et al. Punicalagin Protects against the Development of Methotrexate-Induced Hepatotoxicity in Mice via Activating Nrf2 Signaling and Decreasing Oxidative Stress, Inflammation, and Cell Death. Int J Mol Sci. 2022; 23(20):12334.
[27] ZHANG Y, TAN X, CAO Y, et al. Punicalagin Protects against Diabetic Liver Injury by Upregulating Mitophagy and Antioxidant Enzyme Activities. Nutrients. 2022;14(14):2782.
[28] ZHANG Z, JI C, WANG YN, et al. Maresin1 Suppresses High-Glucose-Induced Ferroptosis in Osteoblasts via NRF2 Activation in Type 2 Diabetic Osteoporosis. Cells. 2022;11(16):2560.
[29] LONG Z, DOU P, CAI W, et al. MiR-181a-5p promotes osteogenesis by targeting BMP3. Aging (Albany NY). 2023;15(3):734-747.
[30] OUYANG J, XIAO Y, REN Q, et al. 7-Ketocholesterol Induces Oxiapoptophagy and Inhibits Osteogenic Differentiation in MC3T3-E1 Cells. Cells. 2022;11(18):2882.
[31] ZHOU M, GRAVES DT. Impact of the host response and osteoblast lineage cells on periodontal disease. Front Immunol. 2022;13:998244.
[32] NAGASHIMA D, ISHIBASHI Y, KAWAGUCHI S, et al. Human Recombinant Lactoferrin Promotes Differentiation and Calcification on MC3T3-E1 Cells. Pharmaceutics. 2022;15(1):60.
[33] TAN AQ, ZHENG YF. The Roles of SNHG Family in Osteoblast Differentiation. Genes . 2022;13(12):2268.
[34] KAN T, HE Z, DU J, et al. Irisin promotes fracture healing by improving osteogenesis and angiogenesis. J Orthop Translat. 2022;37:37-45.
[35] DARJANKI CM, PRAHASANTI C, FITRIA AE, et al. RUNX2 and ALP expression in osteoblast cells exposed by PMMA-HAp combination: An in vitro study. J Oral Biol Craniofac Res. 2023;13(2):277-282.
[36] WANG MY, AN MF, FAN MS, et al. FAEE exerts a protective effect against osteoporosis by regulating the MAPK signalling pathway. Pharm Biol. 2022;60(1):467-478.
[37] DAMANI JJ, DE SOUZA MJ, VANEVERY HL, et al. The Role of Prunes in Modulating Inflammatory Pathways to Improve Bone Health in Postmenopausal Women. Adv Nutr. 2022;13(5):1476-1492.
[38] KERSCHAN-SCHINDL K, PAPAGEORGIOU M, FÖGER-SAMWALD U, et al. Assessment of Bone Microstructure by Micro CT in C57BL/6J Mice for Sex-Specific Differentiation. Int J Mol Sci. 2022;23(23):14585.
[39] BROWN JP, ENGELKE K, KEAVENY TM, et al. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res. 2021;36(11): 2139-2152.
[40] WEE H, KHAJURIA DK, KAMAL F, et al. Assessment of Bone Fracture Healing Using Micro-Computed Tomography. J Vis Exp. 2022;(190): 10.3791/64262.
[41] XIE H, HUA Z, GUO M, et al. Gut microbiota and metabonomics used to explore the mechanism of Qing’e Pills in alleviating osteoporosis. Pharm Biol. 2022;60(1):785-800.
[42] KUNIOKA CT, MANSO MC, CARVALHO M. Association between Environmental Cadmium Exposure and Osteoporosis Risk in Postmenopausal Women: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;20(1):485.
[43] LI Y, ZHANG R, REN M, et al. Experimental study on the effects of simvastatin in reversing the femoral metaphyseal defects induced by sodium valproate in normal and ovariectomized rats. Heliyon. 2022; 8(9):e10480.